Paradoxical and contradictory effects of imatinib in two cell line models of hormone‐refractory prostate cancer

E-ISSN： 1097-0045|75|9|923-935

ISSN： 0270-4137

Source： THE PROSTATE, Vol.75, Iss.9, 2015-06, pp. : 923-935

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

TREATMENT WITH PREDNISOLONE OF HORMONE-REFRACTORY PROSTATE CANCER

By Fuse H. Nozaki T. Fujiuchi Y. Mizuno I. Nagakawa O. Okumura A.

Archives of Andrology, Vol. 52, Iss. 1, 2006-01 ,pp. : 35-38

Informa Healthcare

Access to resources Recommend Favorite

Role of Chemotherapy in Hormone-Refractory Prostate Cancer

Urologia Internationalis, Vol. 70, Iss. 1, 2003-02 ,pp. : 1-14

Karger

Access to resources Recommend Favorite

REDISTRIBUTION OF ANDROGEN RECEPTORS IN ACQUIRED HORMONE-REFRACTORY PROSTATE CANCER CELLS

By Yu D. S. Hsieh D. S. Chang S. Y.

Archives of Andrology, Vol. 52, Iss. 5, 2006-09 ,pp. : 389-395

Informa Healthcare

Access to resources Recommend Favorite

A Weekly Schedule of Docetaxel for Metastatic Hormone-Refractory Prostate Cancer

Oncology, Vol. 66, Iss. 4, 2004-06 ,pp. : 281-287

Karger

Access to resources Recommend Favorite

Hormonal Sensitivity following Endocrine Withdrawal in Hormone-Refractory Prostate Cancer

Urologia Internationalis, Vol. 65, Iss. 1, 2000-08 ,pp. : 28-31

Karger

Access to resources Recommend Favorite